June 25, 2019

The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results.  However, it is not out of the question that a Phase III study can meet its efficacy endpoint, yet still be rejected by the FDA.  This may especially...

Please reload

THE GENE

EXPRESS

Recent News

Nucleic freeze

April 2, 2020

Surface charm

April 2, 2020

Target practice

April 2, 2020

1/4
Please reload

Tags

Please reload

 

Follow us:

©2018 by GeneCentrix, Inc.